Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

Fig. 2

Genetic variants and overall survival (OS) of lung carcinoma patients with EGFR-mutant (M +) or EGFR-wildtype (WT) tumors. A Forest plot showing how variants with a significant impact on PFS affect the OS of patients with EGFR M + tumors treated with EGFR TKIs (in orange). Effects on the OS of patients with EGFR-WT tumors are displayed in blue. B, C Kaplan–Meier curves for PFS. Patients with EGFR-mutant tumors were stratified according to (B) the absence or presence of at least one variant in the KIR3DL1 gene, or (C) the absence or presence of the variant in the KIR3DL2 gene. D Forest plot illustrating the effect of variants with a significant impact on OS for patients with EGFR M + tumors treated with EGFR TKIs (in orange). The effects on the OS of patients with EGFR-WT tumors are displayed in blue. E Heatmap summarizing the effect of all these variants on the OS of patients with EGFR M + tumors

Back to article page

Molecular Cancer

ISSN: 1476-4598